Quick answers
- What is Rabeprazole sodium used for?
- The FDA-approved label (Aciphex, Waylis Therapeutics LLC, January 27, 2026) says: “ACIPHEX delayed-release tablets is a proton pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive or Ulcerative GERD. Treatment of Symptomatic GERD. Healing of Duodenal Ulcers. Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Rabeprazole sodium have a boxed warning?
- No. None of the 36 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Rabeprazole sodium?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Rabeprazole sodium been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Rabeprazole sodium?
- 20 companies list prescription products of Rabeprazole sodium in the FDA NDC Directory, including Bryant Ranch Prepack, Proficient Rx LP and Asclemed USA, Inc..
What Rabeprazole sodium is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ACIPHEX delayed-release tablets is a proton pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive or Ulcerative GERD. Treatment of Symptomatic GERD. Healing of Duodenal Ulcers. Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence. …
— FDA label: Aciphex, Waylis Therapeutics LLC, effective January 27, 2026. Read the full label on DailyMed →
The FDA has 36 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 36 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, delayed release |
|---|---|
| Route | Oral |
| Prescription products | 38 in the FDA NDC Directory |
| Brand names | Aciphex |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| rabeprazole sodium 20 mg tablet, delayed release | Generic | $0.2331 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack6 products
- Proficient Rx LP4 products
- Asclemed USA, Inc.3 products
- Advanced Rx of Tennessee, LLC3 products
- Preferred Pharmaceuticals Inc.3 products
- Direct_Rx2 products
- Remedyrepack Inc.2 products
- A-S Medication Solutions2 products
- St. Mary's Medical Park Pharmacy2 products
- Advanced Rx Pharmacy of Tennessee, LLC1 product
- Phoenix RX LLC1 product
- Golden State Medical Supply, Inc.1 product
- Ascend Laboratories, LLC1 product
- Chartwell RX, LLC1 product
- Advagen Pharma Limited1 product
- Waylis Therapeutics LLC1 product
- Torrent Pharmaceuticals Limited1 product
- Amneal Pharmaceuticals LLC1 product
- Lannett Company, Inc.1 product
- Aurobindo Pharma Limited1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA020973 ACIPHEX | Waylis Therap | August 19, 1999 | 32, latest July 18, 2023 2023: Labeling · 2022: Labeling · 2020: Labeling |
Generic approvals (6)
- ANDA090678Lannett Co Inc · November 8, 2013
- ANDA202376Torrent · November 8, 2013
- ANDA204179Amneal Pharms · July 31, 2015
- ANDA204237Rubicon Research · November 18, 2015
- ANDA205761Quagen · February 17, 2017
- ANDA208644Alkem Labs Ltd · April 24, 2018
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 854868, 854870 |
|---|---|
| SPL set ID of the quoted label | 1eb38279-0237-4967-be7a-c53a826c1138 |
| FDA labels (SPL) | 36 |
| FDA applications | NDA020973, 6 ANDA |
| Active ingredients (FDA) | RABEPRAZOLE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Aciphex, Waylis Therapeutics LLC, effective January 27, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →